Sunday, April 15, 2012

5th generation cephelsporin!

Ceftobiprole is a fifth-generation cephalosporin antibiotic with activity against MRSA, Pseudomonas aeruginosa, and enterococci. It is on Fast track for FDA approval. Ceftobiprole has already been approved for use in Canada and Switzerland.

Ceftobiprole is the first, broad-spectrum, anti-MRSA cephalosporin. It is also the first of antimicrobials to include anti-MRSA and anti-Pseudomonas activity in the spectrum of its coverage - providing single coverage for both. The dosing ris 500 mg IV every 8 hours or every 12 hours. Dosing adjustments may be necessary in patients with renal insufficiency.

No comments:

Post a Comment